A study from Denmark looked at the effectiveness of a high-dose quadrivalent flu vaccine in people aged 65+ compared to a standard dose. During three flu seasons, they randomized 332,438 participants to one of two groups. The main monitored indicator was hospitalization for influenza or pneumonia. In the high-dose group, 0.68% of participants were hospitalized, in the standard-dose group, 0.73%. The study did not find a clear difference in hospitalization rates between the high-dose and standard vaccine. The article also states that GLP-1 agonists (which include liraglutide) are undergoing a large number of studies (112) in various diseases, according to ClinicalTrials.gov.